Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionPlace of product in therapyDisease description

Natural history, survival, and mortality

13 evidence topics · 12 sources

Stage at diagnosis and five-year relative survival, all oral cavity and pharynx cancer
SEER stagePercent of casesFive-year relative survival
Localized“26%”“88.7%”
Regional“55%”“69.7%”
Distant“12%”“36.0%”
Unstaged“6%”“62.3%”
Stage at diagnosis and five-year relative survival, all laryngeal cancer
SEER stagePercent of casesFive-year relative survival
Localized“49%”“79.8%”
Regional“30%”“49.4%”
Distant“15%”“36.0%”
Unstaged“6%”“57.0%”
Median overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC at 4-year follow-up